[Type 2 diabetes mellitus and obesity: should we treat the obesity or the diabetes?].
In this article, we review the results that can be expected after significant weight loss in patients with type 2 diabetes mellitus. We provide consensus-based documentation supported by the American Diabetes Association, the European Association for the Study of Diabetes, and the International Diabetes Federation on the importance of physical exercise, metabolic-bariatric surgery, and drug therapy. Lastly, we report the results of studies published in the last few years on glucagon-like peptide-1 analogs and the new family of oral drugs known as gliflozins, specifically studies published on dapagliflozin.
Departamento de Medicina, Facultad de Medicina de Sevilla, Unidad de Gestión Clínica de Endocrinología y Nutrición, Hospital Universitario Virgen de Valme, Sevilla, España; Miembro de la European Association for the Study of Diabetes, la American Diabetes Association, la Sociedad Española de Endocrinología y Nutrición, la Sociedad Española de Diabetes, la Sociedad Andaluza de Endocrinología y Nutrición y Socio Fundador de la Sociedad Española para el Estudio de la Obesidad. Electronic address: sduran@duransanz.com.
Santiago Durán
SD
García
Máster en Ejercicio y Salud, Universidad de Sevilla, Unidad de Investigación y Ensayos Clínicos de Endocrinología, Hospital Universitario Virgen de Valme, Sevilla, España.
Santiago Durán
SD
Sanz
Cátedra de Endocrinología y Nutrición Clínica, Facultad de Medicina, Universidad de Sevilla, Sevilla, España.
Alejandro Durán
AD
Sanz
D050110:Bariatric Surgery; D001559:Benzhydryl Compounds; D015984:Causality; D015897:Comorbidity; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000378:metabolism / Q000628:therapy; D003927:Diet, Diabetic; D004038:Diet, Reducing; D019468:Disease Management; D019317:Evidence-Based Medicine; D005081:Exercise Therapy; D052216:Glucagon-Like Peptide 1 / Q000819:agonists; D005960:Glucosides / Q000627:therapeutic use; D006801:Humans; D006946:Hyperinsulinism / Q000150:complications / Q000378:metabolism; D007004:Hypoglycemic Agents / Q000145:classification / Q000494:pharmacology / Q000627:therapeutic use; D007333:Insulin Resistance; D024821:Metabolic Syndrome / Q000628:therapy; D009765:Obesity / Q000150:complications* / Q000378:metabolism / Q000628:therapy; D017410:Practice Guidelines as Topic; D051297:Sodium-Glucose Transporter 2; D000077203:Sodium-Glucose Transporter 2 Inhibitors; D015431:Weight Loss
D001559:Benzhydryl Compounds; D005960:Glucosides; D007004:Hypoglycemic Agents; C089180:SLC5A2 protein, human; D051297:Sodium-Glucose Transporter 2; D000077203:Sodium-Glucose Transporter 2 Inhibitors; C529054:dapagliflozin; D052216:Glucagon-Like Peptide 1
Análogos del péptido similar al glucagón tipo 1; Bariatric surgery; Cirugía bariátrica; Dapagliflozin; Dapagliflozina; Diabetes mellitus tipo 2; Ejercicio; Exenatida; Exenatide; Exercise; Gliflozinas; Gliflozins; Gliptinas; Gliptins; Glucagon-like peptide-1 analogs; Liraglutida; Liraglutide; Metabolic syndrome; Obesidad; Obesity; Overweight; Sobrepeso; Síndrome metabólico; Type 2 diabetes mellitus